Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment (Medication [Riluzole, Edaravone, Others], Stem Cell Therapy, Others)
5.2.2. By Type (Sporadic ALS, Familial ALS)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.4. By Company (2023)
5.2.5. By Region
5.3. Market Map

6. North America Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment
6.2.2. By Type
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment
6.3.1.2.2. By Type
6.3.1.2.3. By Distribution Channel
6.3.2. Mexico Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment
6.3.2.2.2. By Type
6.3.2.2.3. By Distribution Channel
6.3.3. Canada Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment
6.3.3.2.2. By Type
6.3.3.2.3. By Distribution Channel

7. Europe Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment
7.2.2. By Type
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment
7.3.1.2.2. By Type
7.3.1.2.3. By Distribution Channel
7.3.2. Germany Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment
7.3.2.2.2. By Type
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment
7.3.3.2.2. By Type
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment
7.3.4.2.2. By Type
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment
7.3.5.2.2. By Type
7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment
8.2.2. By Type
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment
8.3.1.2.2. By Type
8.3.1.2.3. By Distribution Channel
8.3.2. India Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment
8.3.2.2.2. By Type
8.3.2.2.3. By Distribution Channel
8.3.3. South Korea Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment
8.3.3.2.2. By Type
8.3.3.2.3. By Distribution Channel
8.3.4. Japan Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment
8.3.4.2.2. By Type
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment
8.3.5.2.2. By Type
8.3.5.2.3. By Distribution Channel

9. South America Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment
9.2.2. By Type
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment
9.3.1.2.2. By Type
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment
9.3.2.2.2. By Type
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment
9.3.3.2.2. By Type
9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment
10.2.2. By Type
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment
10.3.1.2.2. By Type
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment
10.3.2.2.2. By Type
10.3.2.2.3. By Distribution Channel
10.3.3. UAE Amyotrophic Lateral Sclerosis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment
10.3.3.2.2. By Type
10.3.3.2.3. By Distribution Channel

11. Market Dynamics
11.1. Drivers
11.2. Challenges

12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porters Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape
14.1. Mitsubishi Tanabe Pharma Corporation
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Biogen Inc.
14.3. Brainstorm Cell Therapeutics Ltd.
14.4. Amylyx Pharmaceuticals, Inc.
14.5. Ionis Pharmaceuticals, Inc.
14.6. Sanofi S.A.
14.7. Otsuka Pharmaceutical Co., Ltd.
14.8. Sun Pharmaceutical Industries Ltd.
14.9. Orion Corporation
14.10. AB Science

15. Strategic Recommendations

16. About Us & Disclaimer